Add BrightSurf on Google Email

A comparative analysis of two SARS-CoV-2 vaccines: Insights from Korea University College of Medicine

A recent study published in eClinical Medicine found that the GB510/AS03 vaccine elicited a stronger antibody immune response against the ancestral SARS-CoV-2 strain compared to ChAdOx1-S. The vaccine demonstrated robust safety and efficacy, with no significant safety concerns identified.

SourceKorea University College of Medicine·JournalEClinicalMedicine·TypeRandomized controlled/clinical trial·DateNov 8, 2023

Research examines why mask usage in Japan persists

Research out of Osaka University reveals that many Japanese people continue to wear masks for socio-psychological reasons, including relief and norm. The study found correlations between mask usage motivations and actual mask usage before and after the government downgraded COVID-19's legal status.

SourceOsaka University·JournalInternational Journal of Disaster Risk Reduction·TypeObservational study·DateNov 2, 2023

Risk of admission and death from COVID-19 low overall, but oldest adults remain vulnerable

A new study found that while most residents in British Columbia had been infected with SARS-CoV-2, older adults remained at highest risk of hospitalization and death due to COVID-19. The researchers estimated that the risk of hospitalization for COVID-19 was about 1 in 30 among adults 80 years and older.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·DateOct 30, 2023

Long COVID most prevalent in the most seriously ill

A study published in The Lancet Regional Health – Europe found that individuals with severe COVID-19 infections experienced the highest prevalence of chronic physical symptoms and had the most persistent symptoms for up to two years after diagnosis. In contrast, those who were never bedridden during their infection presented with a sim...

SourceKarolinska Institutet·JournalThe Lancet Regional Health - Europe·TypeObservational study·DateOct 27, 2023

A new era for accurate, rapid COVID-19 testing

Researchers at Osaka University have developed a novel platform that combines nanopore technology with artificial intelligence to detect different coronavirus variants quickly. The platform was tested on 241 saliva samples and detected the Omicron variant 100% of the time.

SourceOsaka University·JournalLab on a Chip·TypeRandomized controlled/clinical trial·DateOct 26, 2023

Post-COVID condition is not linked to ongoing infection or active brain damage

A recent study by the University of Gothenburg found no correlation between post-COVID condition and ongoing viral infection or active brain damage. The study analyzed 25 participants with confirmed post-COVID condition, six without residual symptoms, and 17 control subjects, revealing undetectable SARS-CoV-2 antigens in all samples.

SourceUniversity of Gothenburg·JournalThe Journal of Infectious Diseases·TypeObservational study·DateOct 25, 2023

Penn Medicine research sheds new light on immune response during SARS-CoV-2 breakthrough infections

Researchers identified enhanced B-cell and T-cell responses in fully vaccinated individuals who became infected with SARS-CoV-2, generating immunological memory to prevent severe infection. Vaccine-primed memory T cells play a critical role in preventing severe COVID-19.

SourceUniversity of Pennsylvania School of Medicine·JournalNature Immunology·TypeRandomized controlled/clinical trial·DateOct 19, 2023

Does SARS-CoV-2 infection have urological effects?

A study published in the Journal of Internal Medicine found that SARS-CoV-2 infection may worsen lower urinary tract symptoms in men. The research involved 17,986 men with medication for LUTS, half of whom had COVID-19, and showed a significant increase in urine retention, UTIs, and enlarged prostate issues.

SourceWiley·JournalJournal of Internal Medicine·DateOct 18, 2023

Does COVID-19 affect Alzheimer’s disease risk?

A review in the Journal of Neurochemistry suggests a link between COVID-19 and Alzheimer's disease, with age being the largest contributing factor. Emerging evidence may further support this association, with research assessing influences on AD neuropathology.

SourceWiley·JournalJournal of Neurochemistry·DateOct 18, 2023

Synthetic peptide could reduce vascular problems associated with COVID-ARDS

Researchers have developed a synthetic peptide that could help reduce vascular problems associated with acute respiratory distress syndrome in COVID-19. The peptide, called TIP, works by binding to a subunit of the epithelial sodium channel, which helps maintain barrier function and prevent damage from viral proteins.

SourceMedical College of Georgia at Augusta University·JournalFrontiers in Immunology·DateOct 3, 2023

Trivalent vaccine candidate fights measles, mumps, SARS-CoV-2

Scientists have developed a trivalent vaccine candidate that provides broad and long-lasting protection against COVID-19 infection by delivering the vaccine via the nose. The vaccine triggers a strong neutralizing antibody response and protects mucosal areas, preventing disease symptoms.

SourceOhio State University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateOct 2, 2023

New vaccine technology could protect from future viruses and variants

A new vaccine candidate has shown protection against a range of coronaviruses, including current and future variants, by targeting the critical regions of the virus that it needs to complete its life cycle. The vaccine technology, developed at the University of Cambridge, aims to provide broad-based protection against emerging viruses.

SourceUniversity of Cambridge·JournalNature Biomedical Engineering·TypeExperimental study·DateSep 25, 2023

People with long COVID have distinct hormonal and immune differences from those without this condition

Researchers identified specific blood biomarkers that can accurately identify patients with long COVID, revealing distinct immune and hormone function differences. The study also found abnormal T cell activity, reactivation of latent viruses, and reduced cortisol levels in patients with long COVID.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNature·TypeRandomized controlled/clinical trial·DateSep 25, 2023

How bats evolved to avoid cancer

A new study has found that bats' extraordinary ability to host and survive infections may be linked to their low cancer rates. Researchers sequenced the genomes of two bat species and compared them to other mammals, discovering genetic adaptations that allow bats to tolerate viral infections.

SourceOxford University Press USA·JournalGenome Biology and Evolution·TypeContent analysis·DateSep 20, 2023

COVID-19 brain fog and the role of Tau proteins

Researchers identified a link between SARS-CoV-2 infection and Alzheimer's disease-like cognitive symptoms, triggered by Tau protein hyperphosphorylation. The study found increased Tau levels in infected cells, indicating pathological alterations to the protein.

SourcePNAS Nexus·JournalPNAS Nexus·DateSep 19, 2023

Rapid acting, oral vaccines are coming soon

Researchers have developed a new vaccination method that induces the production of antibodies in mucus, which can disable viruses. This approach has shown promising results in monkeys, suggesting that oral vaccines against SARS-CoV-2 may be more effective and popular than traditional subcutaneous vaccinations.

SourceOxford University Press USA·JournalBiology Methods and Protocols·TypeExperimental study·DateSep 13, 2023

Mount Sinai receives NIH grant to develop vaccines that can protect against many different types of coronaviruses

The Mount Sinai Hospital received a $13 million NIH grant to create vaccines that can protect against various types of coronaviruses. The project aims to develop variant-proof, universal vaccines that offer broad protection against existing and future SARS-CoV-2 variants, pandemic, zoonotic, and seasonal coronaviruses.

Study helps explain SARS-CoV-2 variants’ rapid spread

New SARS-CoV-2 variants, such as BQ.11 and XBB.1.5, bind to cells more tightly and evade antibodies more efficiently than earlier variants, allowing reinfections and breakthrough infections. Previous infection or vaccination can generate antibodies that recognize some proteins on newer variants, reducing the risk of serious illness.

SourceUniversity of Washington School of Medicine/UW Medicine·JournalNature·TypeExperimental study·DateAug 30, 2023

Inhalable molecules neutralize SARS-CoV-2 in mice

Researchers at Affilogic developed nanofitins that inhibit SARS-CoV-2 by binding to its spike proteins, demonstrating quick reach and clearance of the lungs. The technology has potential for treating other infectious respiratory diseases with lower costs and higher accessibility.

SourceCell Press·JournalMolecular Therapy·TypeExperimental study·DateAug 30, 2023

The long-term course of severe long COVID

Patients with severe long COVID often struggle with fatigue and exertion intolerance, with recovery rates varying depending on the initial infection's severity. A recent study found that those with ME/CFS experience little to no improvement in symptoms, while some patients in a second group show gradual improvement over time.

SourceCharité - Universitätsmedizin Berlin·JournalEClinicalMedicine·TypeObservational study·DateAug 28, 2023

New grasp of key COVID-19 protein may lead to a live-attenuated vaccine effective against more variants for longer

Researchers have identified a key protein in SARS-CoV-2 that, when targeted, elicits a robust immune response. A live-attenuated vaccine based on this protein shows promise in preventing disease and offering long-lasting immunity. The approach could target areas of the genome less likely to change with variants.

SourceUniversity of Kansas·JournalProceedings of the National Academy of Sciences·DateAug 28, 2023